^
    Back
    Association details:
    Biomarker:TP53 wild-type
    Cancer:Solid Tumor
    Drug:navtemadlin (KRT-232) (MDM2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

    Excerpt:
    ...- Part 2 patient must show evidence of wild-type (WT) p53 status on somatic tissue specimens as assessed by deoxyribonucleic acid (DNA) sequencing...
    Trial ID:
    ALLIANCE-ABTC-1604
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

    Excerpt:
    ...- Histologically or cytologically confirmed diagnosis of SCLC documented as TP53WT...
    Trial ID:
    NCT05027867
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Invest New Drugs
    Title:

    Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

    Published date:
    07/29/2019
    Excerpt:
    This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). In the dose escalation (n = 39), patients with P53WT refractory solid tumors enrolled to receive once-daily AMG 232 (15, 30, 60, 120, 240, 480, and 960 mg) for seven days every 3 weeks (Q3W)...In patients with P53WT advanced solid tumors or MM, AMG 232 showed acceptable safety and dose-proportional pharmacokinetics, and stable disease was observed.
    DOI:
    10.1007/s10637-019-00840-1